

2024 – 2025 COVID-19 Vaccine Memo

Dear Colleagues,

This memo summarizes the updated 2024-2025 COVID-19 vaccine recommendations for patients of Lucile Packard Children's Hospital (LPCH) Stanford and Clinics for the 2024-2025 season. These are based on the [most recent recommendations](#) from the Centers for Disease Control and Prevention (CDC).

The inpatient and outpatient EMR-based processes for screening and vaccinating patients against SARS-CoV-2 at LPCH Stanford and Clinics will "Go Live" on **September 24, 2024**. We expect that SARS-CoV-2 will continue to circulate throughout the Fall and Winter seasons in conjunction with other respiratory viruses. Receiving an updated COVID-19 vaccination is important to protect our patients and their families.

An updated COVID-19 vaccine has been approved and authorized by the FDA to protect against the currently circulating SARS-CoV-2 variants. Only the Moderna 2024-2025 COVID-19 vaccine will be offered at LPCH Stanford Hospital and select specialty clinics. Both vaccine formulations, for 6 months – 11 years and 12+ years, are now available in pre-filled syringes.

Other important reminders:

- COVID-19 vaccination is recommended for everyone aged ≥ 6 months, including pregnant women, unless contraindicated (see #6 below).** For those aged ≥ 5 years of age, 1 dose of updated 2024-2025 COVID-19 vaccine is recommended.
- Children 6 months through 4 years of age require 2 doses of Moderna for the initial vaccination series.** If receiving Pfizer-BioNTech, 3 doses are required for the initial series. It is preferred to complete all doses in the initial vaccination series with the same vaccine manufacturer. If different manufacturers are used, a 3-dose schedule should be followed. Immunocompromised children in this age group may qualify for additional doses. Refer to [CDC guidance on vaccine interchangeability](#).
- Immunocompromised patients aged 5 years and older who received only 1 -2 doses of previous formulation should complete the 3-dose series using the updated 2024-2025 COVID-19 vaccine from the *same* manufacturer.** Those who have received 3 or more COVID-19 vaccine doses may receive at least one dose of the updated vaccine from *either* manufacturer. Refer to Table 2 in [CDC Interim Clinical Considerations](#) for Use of COVID-19 Vaccine for more information.
- COVID-19 vaccines for patients under 12 years of age are FDA-authorized under Emergency Use Authorization (EUA).** Providers must review and provide the [EUA fact sheet](#) to the patient/caregiver before administering each dose.
- The COVID-19 vaccine may be administered on the same day as other immunizations, including the influenza vaccine or other routine childhood vaccine.** Administer at different injection sites.
- Before ordering COVID-19 vaccine, confirm that the patient meets criteria and evaluate for any of the following precautions/contraindications:**
 - Severe allergic reaction after a previous dose or to a component of a COVID-19 vaccine (**contraindication**)
 - History of diagnosed non-severe allergy to a component of the COVID-19 vaccine
 - History of a non-severe, immediate (onset < 4 hours) allergic reaction after administration of a previous dose of COVID-19 vaccine.
 - History of myocarditis/pericarditis within 3 weeks after a dose of any COVID-19 vaccine
 - History of Multisystem Inflammatory Syndrome in children or adults (MIS-C or MIS-A)

Additional information regarding the COVID-19 vaccination is available at the links below:

- Fact Sheet for Healthcare Providers ([6 months – 11 years EUA authorization](#)) ([12+ years Spikevax™](#))
- CDC COVID-19 Vaccination Schedule Tables ([General Population](#)) ([Immunocompromised](#))
- [CDC Interim Clinical Considerations for Use of COVID-19 Vaccines](#)

Please contact us with any questions or concerns. Thank you for helping to ensure the health and safety of our patients.

Sincerely,

Lauren Puckett, PharmD, BCIDP, Lauren Kushner, MD, Hayden Schwenk, MD, MPH, and Shabnam Gaskari, PharmD, on behalf of the LPCH Stanford Integrated Infectious Diseases Program